Gaudium IVF and Women Health Limited

NSE: GAUDIUMIVFHealthcare Service Provider

Share price

₹105.80

+1.36% close of 9 Oct 2026

Market cap ₹756 CrP/E 32.5 (as of 8 Oct 2026)

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹756 Cr

P/E ratio

32.5

P/B ratio

5.0

ROCE

29.3%

ROE

24.6%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹158.1652-week low ₹70.67

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Fewer than three years of filings — too early to judge growth.

Whether it grew faster than its sector

It grew 29.0% a year against a sector median of 13.1% — 15.9 percentage points faster.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 1.5 times its growth rate, on earnings growth of 22%.

	Profit growth	Price per ₹1 profit	Per 1% growth
Gaudium IVF and Women Health Limited — this one	22%/yr	32.5×	₹1.5
Dr. Lal Path Labs Ltd.	30%/yr	56.7×	₹1.9
Vijaya Diagnostic Centre Limited	24%/yr	76.5×	₹3.2
Metropolis Healthcare Limited	11%/yr	51.6×	₹4.7
Thyrocare Technologies Limited	36%/yr	44.3×	₹1.2
Nephrocare Health Services Limited	103%/yr	73.7×	—

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Healthcare Service Provider), it ranks 4 of 12 on returns, 3 of 11 on growth, 4 of 12 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 29.3% on capital, ahead of 67% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹42 crore of cash from the business and spent ₹34 crore on plant and equipment, with ₹8 crore to spare; it still raised ₹91 crore from lenders and shareholders. And the profit is real: of every 100 rupees it reported over 5 years, about 55 arrived as cash. Its cash comes back more slowly than it used to: it went from being waiting 61 days for its cash to waiting 91 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 9 checks clear · 78%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue up 9% and profit down 42% on expansion spending, with FY27 growth now guided at 30%

Announced 13 Aug 2026 · Consolidated · Unaudited

Revenue

₹19 Cr

Revenue vs last quarter

-36.2%

Net profit

₹2 Cr

Profit vs last quarter

-78.8%

Net margin

9.2%

EPS

₹0.25

Earnings call transcript · 14 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap: ₹756 Cr
Prev close: ₹105.80
52w High: ₹163
52w Low: ₹69.2
Enterprise value: ₹772 Cr
Beta: 1.4
Price CAGR 1y: —
Price CAGR 3y: —
Price CAGR 5y: —
Price CAGR 10y: —

Ratios

Return on assets: 12.4%
PEG ratio: 1.5
P/E ratio: 32.5
P/B ratio: 5.0
EV / EBITDA: 20.5
Industry P/E: 44.1
ROCE: 29.3%
ROCE 5y average: 49.8%
ROE: 24.6%
Debt / Equity: 0.2
Interest coverage: 11.7
Dividend yield: 0.0%
ROE 3y average: 34.0%
ROE last year: 25.0%

Annual P&L

Annual revenue: ₹104 Cr
Annual profit: ₹24 Cr
Operating margin: 36.0%
Net profit margin: 23.1%
EBITDA margin: 36.5%
Sales growth 3y: 33.2%
Sales growth 5y: —
Profit growth 3y: 22.0%
Profit growth 5y: —
EPS: ₹3.4
Sales growth TTM: 48.0%
Profit growth TTM: 28.0%
Dividend payout: 0.0%

Quarter P&L

Sales latest quarter: ₹19 Cr
Profit latest quarter: ₹2 Cr
YoY quarterly sales growth: 9.1%
YoY quarterly profit growth: -42.0%
OPM latest quarter: 12.5%

Balance Sheet

Book Value: ₹21.1
Face Value: ₹5.0
Total debt: ₹25 Cr
Total cash: ₹9 Cr
Borrowings: ₹25 Cr
Reserves / Equity: 3.2

Cash Flow

Operating cash flow: ₹7 Cr
Free cash flow: ₹1 Cr
FCF yield: -0.4%
Net cash flow: ₹2 Cr

Shareholding

Promoter holding: 71.3%
FII holding: 3.0%
DII holding: 2.2%
Public holding: 23.5%

Peer comparison

Company	Price ₹	P/E	Mkt cap ₹ Cr	Div yield %	Profit qtr ₹ Cr	Profit var %	Sales qtr ₹ Cr	Sales var %	ROCE %
Dr Lal Pathlabs	1,945.10	58.1	32,648	0.72	170.5	28.0	797.7	19.1	28.0
Vijaya Diagnost.	1,462.40	80.3	15,062	0.14	53.1	37.6	231.0	22.8	20.5
Metropolis Healt	541.45	54.0	11,233	0.37	56.9	25.8	450.2	16.6	17.8
Thyrocare Tech.	513.05	45.2	8,166	1.82	51.3	34.1	240.0	24.3	35.4
Nephrocare Health Services	641.60	75.8	6,452	0.00	32.0	34.9	281.8	23.7	15.3
Krsnaa Diagnost.	548.10	18.0	1,778	0.36	15.8	-19.1	210.7	19.9	12.7
Suraksha Diagno.	321.70	46.8	1,675	0.16	12.9	38.4	87.7	20.8	17.3
Gaudium IVF	107.50	33.8	782	0.00	1.8	-42.0	19.4	9.1	29.3
Median	321.70	33.8	1,143	0.00	11.0	28.0	95.2	19.1	20.5

Competes with: Dr. Lal Path Labs Ltd., Krsnaa Diagnostics Limited, Metropolis Healthcare Limited, Nephrocare Health Services Limited, Suraksha Diagnostic Limited, Thyrocare Technologies Limited, Vijaya Diagnostic Centre Limited

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026

Line item	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	32	14	27	18	32	25	30	19
Expenses		8.76	18	13	18	18	18	17
Material Cost						0	0	0
Change in Inventories						0.94	0.33	-0.80
Purchases of Stock-in-Trade						9.76	7.93	7.07
Employee Cost						2.14	2.10	2.28
Other Expenses						5.12	7.82	8.39
Operating Profit		5.66	8.72	5.15	14	6.56	12	2.43
OPM %	40	39	32	29	43	27	40	13
Other Income		0	0.23	0	0.15	0.10	0.18	1.12
Exceptional items (within Other Income)						0	0	0
Interest		0.39	0.43	0.50	0.51	1.20	1.29	0.38
Depreciation		0.58	0.36	0.61	0.61	0.49	0.64	0.72
Profit before tax		4.69	8.16	4.04	13	4.97	10	2.45
Tax %		28	21	24	27	27	20	28
Net Profit		3.40	6.46	3.07	9.38	3.63	8.36	1.78
EPS in Rs		0.55	1.05	0.50	1.53	0.59	1.15	0.24
Diluted EPS in Rs						0.59	1.34	0.25

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026

Line item	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	37	44	48	71	104	106
Expenses	23	24	28	42	67	71
Material Cost					0
Change in Inventories					3.69
Purchases of Stock-in-Trade					30
Employee Cost					7.99
Other Expenses					25
Operating Profit	14	20	19	29	38	35
OPM %	37	46	41	41	36	33
Other Income	0	0	0	0	0	2
Exceptional items (within Other Income)					0
Interest	1	0	1	2	3.49	3
Depreciation	1	1	2	2.05	2.55	2
Profit before tax	12	18	17	25	32	31
Tax %	26	26	38	25	24
Net Profit	9	14	10	19	24	23
EPS in Rs	89	137	104	3.12	3.36	3.51
Diluted EPS in Rs					3.92
Dividend Payout %	0	0	0	0	0

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years: —
5 years: —
3 years: 33%
TTM: 48%

Compounded profit growth

10 years: —
5 years: —
3 years: 22%
TTM: 28%

Return on equity

10 years: —
5 years: 41%
3 years: 34%
Last year: 25%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated

Line item	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	0.99	0.99	0.99	31	36
Reserves	8	22	26	16	116
Borrowings	6	12	17	21	25
Other Liabilities	3	2	7	22	16
Total Liabilities	18	37	51	89	193
Fixed Assets	4	18	19	18	30
CWIP	0	0	0	7	0
Investments	0	0	0	5	5
Other Assets	14	18	32	58	158
Total Assets	18	37	51	89	193

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated

Line item	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-1	24	3	9	7.25
Cash from Investing Activity	-1	-16	-5	-15	-88
Cash from Financing Activity	3	5	-1	2	82
Net Cash Flow	0	13	-3	-5	2
Free Cash Flow	-2	9	1	-0	0.28

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated

Line item	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	65	8	104	170	187
Inventory Days	29	111	168	175	38
Days Payable	114	77	62	338	133
Cash Conversion Cycle	-20	41	210	7	92
Working Capital Days	61	-52	-15	44	91
ROCE %		76	45	49	29

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026

Line item	Mar 2026	Jun 2026
Promoters	71	71
FIIs	6.70	3.01
DIIs	2.63	2.22
Public	19	23
No. of Shareholders	19,854	21,910

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +31.8% (₹80.26 → ₹105.80)Brick size ₹6.59 (fixed)Bricks 32

Price moved up one brickPrice moved down one brickLast close ₹105.80 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Gaudium IVF and Women Health Limited. Open one to see why it matters.

24 Sept, 21:44 IST · Company event · medium impact

Gaudium IVF and Women Health Limited — commencement of commercial operations at Company's new IVF Centre/Hub at Gurgaon, Haryana

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector: Healthcare
Industry: Healthcare Service Provider
Classification: Healthcare › Healthcare Service Provider
ISIN: INE0P8B01020

News impact

Big market events that reach Gaudium IVF and Women Health Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

No dividends, splits or big trades on record.

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.